Opens in a new tab or window The FDA approved tapinarof cream 1% (Vtama) for eczema in individuals ages 2 years and older, drugmaker Organon announced on Monday. Approval of the topical aryl ...

She was prescribed steroid creams, but this has caused the 27-year-old more agony as she now suffers from topical steroid withdrawal ... such as eczema. At its worst she is unable to able to ...

By Stephen Beech A new way of treating common inflammatory skin conditions such as eczema is on the horizon, according to a ...

A daily cream containing a GluK2-activating compound could therefore be a promising way to prevent several inflammatory skin conditions.

Whether it's a red and itchy flare-up or patches of dry, sore skin, eczema can be a debilitating skin condition for the 15 ...

An aryl hydrocarbon receptor agonist, tapinarof cream, 1% was first approved in May 2022 for the topical treatment of ... including the Eczema Area and Severity Index score improvement of at ...

After trying many topical steroids throughout the ... Zoryve is also a steroid free cream which helps to calm the eczema. For patients who cannot get their skin under control with creams or ...

The introduction of yet another targeted topical anti-inflammatory ... with roflumilast and tapinarof creams have not been conducted specifically for hand eczema, but Golant cited case reports ...

Some cosmetics companies are marketing estrogen-infused face creams and serums to people in menopause. Do they work?

And when the mice received a topical cream containing SYM2081 before the induction of rosacea- or eczema-like symptoms, skin inflammation and other symptoms of disease were much milder.

A topical treatment is a medicated ointment, cream, lotion, or other product that can be applied directly to the skin. Many cases of mild to moderate psoriasis may be treatable with topical ...

which is also known as eczema. Organon’s Vtama, a topical cream originally approved for plaque psoriasis in 2022, is now cleared to treat AD, the company said early Monday. The nod came three ...